Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Favrille drug fails secondary goal
An interim analysis of the secondary endpoint indicated that FavId did not demonstrate a statistically significant difference between treatment and control groups in response improvement. The primary endpoint
An interim analysis of the secondary endpoint indicated that FavId did not demonstrate a statistically significant difference between treatment and control groups in response improvement. The primary endpoint
The phase I trial is an evaluation in healthy overweight and obese subjects of the safety, pharmacokinetics, and pharmacodynamics of single rising oral doses of NGD-4715. The study
Data showed that the first primary efficacy endpoint of the study of finding a tolerable dosage regimen ensuring continuous suppression of testosterone at castration level was achieved at
In the first study reported, patients with high cholesterol on stable doses of statins were treated with ISIS 301012 for five weeks. Patients who received 300 mg of
The primary objective of the dose-escalating phase Ib trial, which included patients with systemic lupus erythematosus (SLE) in 6 cohorts, was to determine the safety and tolerability of
The study showed that the two drugs TSA and SAHA decreased cholesterol deposits in the walls of arteries. The two drugs are part of a class of drugs
Enbrel showed strong safety profile for extended periods of use. In the studies, rates of serious adverse events and serious infections remained low. The numbers of observed malignancies,
Over the past two years, there has been documented concern about the cardiovascular safety of some pain relievers and arthritis treatments. Manufacturers of naproxen had previously been asked
RTA 744 is a new anticancer drug that crosses the blood-brain barrier and shows significant potential for the treatment of brain cancers. The drug has demonstrated appropriate pharmacokinetics
The types of patients who are at-risk for serious infection if exposed to the virus are immune compromised pediatric or adult patients, infants less than one year old,